LE WE PMID CA
Omalizumab ttCD202038Omalizumab ttCD20

81C6 ttTenascin

Abatacept ttCTLA4Conjugate

Abciximab ttGPIIAIIIB

Adalimumab ttTNFalpha

AIN457

Alemtuzumab ttCD52

AMG386 ttAngiopoietin1 ttAngiopoietin2

Antibodies (therapeutic use)

Asthma (BASKET)

Atacicept ttBlys ttAPRIL

Bapineuzumab ttAmyloidBeta

Basiliximab ttIL2R

Belatacept ttCD80 ttCD86

Belimumab ttBLyS

Bevacizumab ttVEGF

Brentuximab vedotin ttCD30

Briakinumab ttIL12 ttIL23

Canakinumab ttIL1beta

Catumaxomab ttEpCAM ttCD3 linkerAb

Certolizumab ttTNFalpha

Cetuximab ttEGFR

Churg Strauss syndrome

Daclizumab ttIL2R

Dalotuzumab ttIGF1R

Denosumab ttRANKL

Eculizumab ttFactorH

Efalizumab ttLFA1

Epratuzumab ttCD22

Etanercept ttTNFalpha

FactorIXFc ttFactorIX

FactorVIIIFc ttFactorVIII

Farletuzumab ttFolateRalpha

Figitumumab ttIGF1R

Galiximab ttCD80

Gemtuzumab ozogamicin ttCD33

Girentuximab ttCarbonicAnhydraseIX

Golimumab ttTNFalpha

Hyper Immunoglobulin E syndrome

Ibritumomab tiuxentan yttrium ttCD20

Infliximab ttTNFalpha

Inotuzumab ozogamicin ttCD22

Ipilimumab ttCTLA4

Mepolizumab ttIL5

Motavizumab ttRSVirus

MuromonabCD3 ttCD3

Naptumomab estafenatox tt5T4

Natalizumab ttIntegrinalpha4

Necitumumab ttEGFR

Nimotuzumab ttEGFR

Obinutuzumab ttCD20

Ocrelizumab ttCD20

Ofatumumab ttCD20

Omalizumab ttCD20

Otelixizumab ttCD3

Pagibaximab ttLipoteichoicAcidStaphlococcus

Palivizumab ttRSVirusFprotein

Panitumomab ttEGFR

Pertuzumab ttHER2

Ramucirumab ttVEGFR2

Ranibizumab ttVEGF

Raxibacumab ttAnthrax

REGN88 ttIL6R

Reslizumab ttIL5

Rilonacept ttIL1R

Rituximab ttCD20

Solanezumab ttAmyloidBeta

T1H ttCD6

Tanezumab ttNGF

Teplizumab ttCD3

Tocilizumab ttIL6

Tositumomab ttCD20

Trastuzumab emtansine ttHER2

Trastuzumab ttHER2

Tremelimumab ttCLTA4

Ustekinumab ttIL12 ttIL23

Vedolizumab ttIntegrina4b7

Zalutumumab ttEGFR

Zanulimumab ttCD4

2004  
1
Omalizumab: where does it fit into current asthma management?
[15055248] Cleve Clin J Med 71(3): 251-61 (2004)
2008  
2
Current and future applications of the anti-IgE antibody omalizumab.
[19707429] Biologics 2(1): 67-73 (2008)
2009  
3
Omalizumab and other new drug therapies occupy a small space in asthma disease management.
[19326961] J Manag Care Pharm 15(3): 289-93 (2009)
2009  
4
Omalizumab has a place in therapy for asthma disease management.
[19326960] J Manag Care Pharm 15(3): 284-8 (2009)
2005  
5
Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
[16179127] Acta Pharm 55(2): 123-38 (2005)
2007  
6
A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
[18472983] Ther Clin Risk Manag 3(4): 613-9 (2007)
2009  
7
Omalizumab for the treatment of severe persistent allergic asthma.
[19804687] Health Technol Assess 13 Suppl 2(): 31-9 (2009)
2008  
8
Omalizumab: the evidence for its place in the treatment of allergic asthma.
[20694084] Core Evid 3(1): 55-66 (2008)
2005  
9
Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody.
[15748543] Dermatol Online J 11(1): 2 (2005)
2008  
10
Severe asthma and the omalizumab option.
[18489791] Clin Mol Allergy 6(-): 4 (2008)
2009  
11
Effects of omalizumab on markers of inflammation in patients with allergic asthma.
[19839977] Allergy 64(12): 1728-36 (2009)
2001  
12
Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis.
[11704613] Am J Respir Crit Care Med 164(8 Pt 2): S18-21 (2001)
2001  
13
Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders.
[11704611] Am J Respir Crit Care Med 164(8 Pt 2): S6-11 (2001)
2006  
14
Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications.
[16478867] Chest 129(2): 466-74 (2006)
2002  
15
Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
[11958741] Allergol Immunopathol (Madr) 30(2): 94-9 (2002)
2009  
16
Churg-strauss syndrome in patients treated with omalizumab.
[19411292] Chest 136(2): 507-18 (2009)
2011  
17
Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.
[21410369] N Engl J Med 364(11): 1005-15 (2011)
2011  
18
Antibody-based therapeutics to watch in 2011.
[21051951] MAbs 3(1): 76-99 (2011)
2010  
19
Antibodies to watch in 2010.
[20065640] MAbs 2(1): 84-100 (2010)
2009  
20
Monoclonal antibodies and other biologic agents in the treatment of asthma.
[20065638] MAbs 1(3): 237-46 (2009)
2008  
21
2004  
22
Omalizumab: efficacy in allergic disease.
[15507883] Panminerva Med 46(2): 141-8 (2004)
2011  
23
T cell activity in successful treatment of chronic urticaria with omalizumab.
[21791043] Clin Mol Allergy 9(-): 11 (2011)
2011  
24
Omalizumab in allergic diseases, a recent review.
[22053590] Asian Pac J Allergy Immunol 29(3): 209-19 (2011)
2009  
25
Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations.
[20232578] Asian Pac J Allergy Immunol 27(4): 233-6 (2009)
PMC   
26
Loss of asthma control after cessation of omalizumab treatment: real life data.
[24683390] Postepy Dermatol Alergol 31(1):1-5 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Omalizumab ttCD20

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia